Release Date: January 7, 2026
Expiration Date: January 7, 2027
Activity Overview
This educational activity is an archive of the live presentation held on December 5, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, NPs/PAs, pharmacists, and other HCPs involved in the diagnosis and treatment of AML.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate personalized care plans for patients with AML aligned with guideline-recommended molecular testing and risk stratification protocols
- Evaluate emerging approaches for the management of patients with AML in the frontline, maintenance, and relapsed/refractory settings
- Integrate evidence from recent clinical trials within the framework of treatment paradigms for AML
- Develop effective strategies to monitor for and manage treatment-associated adverse events in patients with AML
Naval Daver, MD
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Director- Leukemia Research Alliance Program
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Agios, Amgen, Arog, Astellas, Bristol-Myers Squibb, Celgene, Daiichi-Sankyo, Genentech, Gilead, ImmunoGen, Jazz, KITE, Novartis, Pfizer, Servier, Shattuck Labs, Stemline/Menarini, Syndax, Trillium; Grant/Research Funding (to institution): AbbVie, Amgen, Astellas, BristolMeyers Squibb, Daiichi-Sankyo, FATE Therapeutics, Genentech, Gilead, Glycomimetics, Hanmi, ImmunoGen, KITE, Novimmune, Pfizer, Servier, Trillium, rovagene.
Daniel A. Pollyea, MD
University of Colorado
Professor of Medicine, Division of Hematology
University of Colorado
Denver, CO
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Abbvie, Astellas, Beigene, Bristol Myers Squibb, Genmab, Geron, Janssen, Kura, MEI, Oncoverity, Qihan, Rigel, Ryvu, Sanofi, Servier, Syndax, Taiho; Grant/Research Funding (to institution): Abbvie, Bristol Myers Squibb, Karyopharm, Teva
Gail J. Roboz, MD
Professor of Medicine
Director, Leukemia Program
Weill Cornell Medicine
New York-Presbyterian Hospital
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, Celgene, Daiichi Sankyo, Ellipses Pharma, Geron, GlaxoSmithKline, GlycoMimetics, Janssen, Jasper Pharmaceuticals, Jazz Pharmaceuticals, Molecular Partners, MorphoSys, Novartis, OncoPrecision, Oncoverity, Pfizer, Rigel, Roche, Syndax; Grant/Research Funding: Janssen
Amer Zeidan, MBBS, MHS
Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale University
Yale Cancer Center
New Haven, CT
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Agios, Akeso Pharma, ALX Oncology, Amgen, Astellas, BeiGene, BioCryst, Boehringer-Ingelheim, Bristol-Meyers Squibb, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Faron, Genentech, Geron, Gilead, Glycomimetics, Hikma, Janssen, Karyopharm, Keros, Kura, Kyowa Kirin, Lava Therapeutics, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Servier, Sumitomo, Syndax, Syros, Taiho, Takeda, Treadwell, Vincerx, Zentalis; Grant/Research Funding: AbbVie, Amgen, Astex, Bristol-Meyers Squibb, Celgene, Geron, Kura, Novartis, Otsuka, Shattuck Labs, Syros.
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.